Assembly Biosciences Files Q1 2024 10-Q
Ticker: ASMB · Form: 10-Q · Filed: 2024-05-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, collaboration
Related Tickers: GILD
TL;DR
**ASMB Q1 10-Q filed. Financials and biz updates out.**
AI Summary
Assembly Biosciences, Inc. filed a 10-Q for the period ending March 31, 2024. The company reported financial results and provided updates on its business operations. Key details regarding their pharmaceutical preparations business and any significant financial transactions or agreements are outlined in this filing.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for Assembly Biosciences, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Assembly Biosciences faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2834 — SIC Code (Indicates the company operates in Pharmaceutical Preparations)
Key Players & Entities
- ASSEMBLY BIOSCIENCES, INC. (company) — Filer
- Gilead Sciences, Incorporated (company) — Mentioned in relation to an Option, License and Collaboration Agreement
- 20240331 (date) — Reporting period end date
- 20240508 (date) — Filing date
FAQ
What were Assembly Biosciences' total assets as of March 31, 2024?
The filing does not explicitly state the total assets figure in the provided snippet.
What is the company's primary business segment?
The company's Standard Industrial Classification (SIC) code is 2834, indicating its primary business is in Pharmaceutical Preparations.
Has Assembly Biosciences entered into any new significant agreements recently?
The filing mentions an 'Option, License and Collaboration Agreement' with 'Gilead Sciences, Incorporated'.
What is the fiscal year end for Assembly Biosciences?
The fiscal year end for Assembly Biosciences is December 31.
When was the company formerly known as Ventrus Biosciences Inc.?
The date of the name change from Ventrus Biosciences Inc. to Assembly Biosciences, Inc. was February 11, 2008.
From the Filing
0000950170-24-055680.txt : 20240508 0000950170-24-055680.hdr.sgml : 20240508 20240508161540 ACCESSION NUMBER: 0000950170-24-055680 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240508 DATE AS OF CHANGE: 20240508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 24926299 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 10-Q 1 asmb-20240331.htm 10-Q 10-Q false 0001426800 Q1 --12-31 Non-accelerated Filer .1429 .0588 .0833 .0833 .0833 http://fasb.org/us-gaap/2023#CashEquivalentsMember http://fasb.org/us-gaap/2023#CashEquivalentsMember http://fasb.org/us-gaap/2023#CashEquivalentsMember http://fasb.org/us-gaap/2023#CashEquivalentsMember http://fasb.org/us-gaap/2023#CashEquivalentsMember http://fasb.org/us-gaap/2023#CashEquivalentsMember http://fasb.org/us-gaap/2023#CashEquivalentsMember http://fasb.org/us-gaap/2023#CashEquivalentsMember 0001426800 2023-01-01 2023-03-31 0001426800 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001426800 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001426800 us-gaap:RetainedEarningsMember 2023-12-31 0001426800 srt:MaximumMember asmb:OptionLicenseAndCollaborationAgreementMember asmb:RegulatoryAndCommercialMilestonesMember asmb:GileadSciencesIncorporatedMember 2023-10-01 2023-10-31 0001426800 asmb:OptionLicenseAndCollaborationAgreementMember asmb:GileadSciencesIncorporatedMember 2023-10-01 2023-10-31 0001426800 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001426800 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember asmb:USAndForeignCommercialPaperMember 2023-12-31 0001426800 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001426800 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001426800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001426800 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 srt:MinimumMember 2023-01-01 2023-03-31 0001426800 2023-03-31 0001426800 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001426800 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:MoneyMarketFundsMember 2023-12-31 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001426800 srt:MaximumMember 2024-01-01 2024-01-31 0001426800 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001426800 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001426800 asmb:EquityAgreementsMember us-gaap:CommonStockMember asmb:GileadSciencesIncorporatedMember 2024-03-31 0001426800 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember asmb:USAndForeignCommercialPaperMember 2023-12-31 0001426800 us-gaap:CommonStockMember 2022-12-31 0001426800 us-gaap:MoneyMarketFundsMember 2024-03-31 0001426800 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001426800 asmb:CommonStockSubjectToPurchaseUnderEmployeeStockPurchaseProgramMember 2023-01-01 2023-03-31 000142680